Anpath Group, Inc. Announces Addition of MRSA and VRE Claims for Its EnviroTru(R) Di...(t acceptable to trade one problem for an...),Health

Date:6/4/2008

t acceptable to trade one problem for another by using potentially harmful chemicals to clean and disinfect. ESI has a single goal - reduce biological risks by destroying a wide range of disease-causing microorganisms with minimum risk to our customer, surfaces and the environment."

Methicillin Resistant Staphylococcus aureus (MRSA) is a bacterium responsible for difficult-to-treat infections in humans. MRSA is a resistant variation of the common bacterium Staphylococcus aureus. It has evolved an ability to survive treatment with beta-lactam antibiotics, including penicillin, methicillin, and cephalosporins. MRSA was discovered in 1961 in the UK and it is now found worldwide, and is often referred to in the press as a "superbug". In the past decade or so the number of MRSA infections in the United States has increased significantly. At the same time, a growing number of cases were noted in schools around the nation, with many closing their doors to scrub down their facilities. After the death of a 17-year-old Virginia student, the school district closed all 21 schools for cleaning. A 2007 report in Emerging Infectious Diseases, a publication of the Centers for Disease Control and Prevention (CDC), estimated that the number of MRSA infections treated doubled nationwide, from approximately 127,000 in 1999 to 278,000 in 2005, while at the same time deaths increased from 11,000 to more than 17,000. Another study led by the CDC and published in the October 17, 2007 issue of the Journal of the American Medical Association estimated that MRSA would have been responsible for 94,360 serious infections and associated with 18,650 hospital stay-related deaths in the United States in 2005. These figures suggest that MRSA infections are responsible for more deaths in the U.S. each year than AIDS.

Enterococci are bacteria that are normally present in the human intestines and in the urinary tract and are often found in the environment. These bacteria can sometimes cau
'/>"/>

SOURCE Anpath Group, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro)
2. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
3. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
4. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
5. Wound Management Technologies, Inc. Announces Evidence Based Study
6. ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
7. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
8. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
9. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
10. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
11. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting